PBS needs to reflect renal benefit of SGLT2 inhibitors: researchers
New modelling shows thousands of lives could be saved through prevention of diabetes-related end-stage kidney disease, they say
The criteria for government funding of SGLT2 inhibitors need to be updated to better reflect their potential to improve renal outcomes in patients with type 2 diabetes, leading Australian researchers say.
The Baker Heart and Diabetes Institute-led team has also called for a shift away from a ‘glucose-centric’ view of the drugs and for clinicians and regulators to broaden their focus to the potential for renal and cardiovascular benefits.
